The Digital Breast Tomosynthesis (DBT) in the Oslo Mammography ..

DBT should be used as an adjunct to conventional 2D breast imaging, not as a replacement, according to the FDA. With that, many breast imagers believe in the technology combination, one even predicting it could become an industry standard. “We’re finding more cancers with tomosynthesis, and we have a reduced recall rate,” says Jaime Geisel, MD, an assistant professor of diagnostic radiology at the Yale University School of Medicine. “If we can reduce false-positives with mammography and tomosynthesis, then maybe we have a better screening test. The new gold standard could be 2D with 3D.”

of Oslo University Hospital Ullevaal

Study population flow chart. DBT = digital breast tomosynthesis, DM = digital mammography

The study is part of the Oslo Tomosynthesis Screening Trial, ..

Clinicians don’t always rapidly adopt new medical technologies. Marshall says Hologic is pleased with tomosynthesis’ rate of adoption in the United States, especially compared with the rate at which its predecessor technology, digital mammography, was accepted. The company installed more 3D systems in the first year following approval than it did the first year following approval of its first 2D system. He attributes some of this difference to the fact that Hologic’s 2D system was designed for conversion to a 2D/3D system with a simple software upgrade. “Many of our customers were able to plan for and make the transition with little difficulty,” he says.

One Rule To Live By Essay - Oslo Study Tomosynthesis

CHICAGO - A major new study being presented at the annual meeting of the Radiological Society of North America (RSNA) has found that digital breast tomosynthesis, also known as 3-D mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women with dense breasts.

Summary of cancer characteristics. DBT = digital breast tomosynthesis, DM = digital mammography

The study was based on 12,631 screening ..

The researchers compared cancer detection using full-field digital mammography (FFDM) versus FFDM plus digital breast tomosynthesis in 25,547 women between the ages of 50 and 69. Breast density was classified based on the American College of Radiology's Breast Imaging-Reporting and Data System (BI-RADS). The BI-RADS breast density scale runs from 1 to 4, with 1 being the least dense and 4 being the most dense.

arm Oslo Tomosynthesis Screening ..

Dr. Skaane and colleagues have been studying tomosynthesis as a promising breast cancer screening option that addresses some of the limitations of mammography by providing 3-D views of the breast.

The Tomosynthesis Trial in Bergen ..

Breast tomosynthesis deconstructs and separates breast tissue into thin cross sectional slices, so that the radiologist can see clearly what lies within the breast, free from the confusion of superimposed tissues. The ability to review breast tissue in high resolution, one millimetre slices provides radiologists the added confidence,1 to significantly reduce recall rates4. It has also been shown to find cancers missed with 2D mammography.3

The Oslo study of tomosynthesis in the Oslo …

"Tomosynthesis could be regarded as an improvement of mammography and would be much easier than MRI or ultrasound to implement in organized screening programs," Dr. Skaane said. "So the intention of our study was to see if tomosynthesis really would significantly increase the cancer detection rate in a population-based mammography screening program."

IMS, systems for digital mammography, tomosynthesis …

The researchers compared cancer detection using full-field digital mammography (FFDM) versus FFDM plus digital breast tomosynthesis in 25,547 women between the ages of 50 and 69. Breast density was classified based on the American College of Radiology's Breast Imaging-Reporting and Data System (BI-RADS). The BI-RADS breast density scale runs from 1 to 4, with 1 being the least dense and 4 being the most dense.

The Oslo Breast Cancer Screening Trial Concludes that …

The Malmö Breast Tomosynthesis Screening Trial is a prospective population-based one-arm study with a planned inclusion of 15000 participants; a random sample of women aged 40–74 years eligible for the screening programme. This is an explorative analysis of the first half of the study population (n = 7500). Participants underwent one-view DBT and two-view digital mammography (DM), with independent double reading and scoring. Primary outcome measures were detection rate, recall rate and positive predictive value (PPV). McNemar's test with 95 % confidence intervals was used.